6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGNPRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2023.

Commission File Number: 001-40627

SOPHiA GENETICS SA

(Exact name of registrant as specified in itscharter)

Rue du Centre172

CH-1025 Saint-Sulpice

Switzerland

(Address of principalexecutive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBIT INDEX

Exhibit 99.1

SOPHiA GENETICS Expands Partnership with AstraZenecato include Multimodal Approaches for Cancer Drug Development

The expanded partnership aims to leverage theglobal SOPHiA DDM™ platform and multimodal algorithmic capabilities to lead a new era of precision oncology by improving early patientidentification and diagnosis, optimizing clinical development, and accelerating adoption of innovative medications along the care pathway

Boston andLausanne, Switzerland – February 13, 2023 – SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading cloud-native global data-sharing network and health analytics platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio. The multimodal approach will go beyond a single data modality, combining radiomics analysis of medical imaging data, molecular data, digital pathology, clinical and biologic data for a more comprehensive assessment of multimodal signatures leveraging proprietary AI and machine learning technology. Together, the companies will examine ways to accelerate clinical trials, support evidence generation for market access, and improve clinical decision-making, helping clinicians to select the best possible treatments.

SOPHiA GENETICS is able to support this vision in practice today. In parallel, SOPHiA GENETICS launched its own real-world DEEP-Lung-IV clinical study to leverage its multimodal machine learning-powered analytics capabilities to identify multimodal predictive signatures of response to immunotherapy for patients with advanced lung cancer.

“AstraZeneca is a global leader in innovative oncology therapeutics and has built one of the most diverse and robust oncology portfolios and R&D pipelines in the industry. Building on our existing partnership with AstraZeneca, notably to expand access to HRD testing, we are incredibly excited to deepen our collaboration to multimodal approaches that will further enable their precision oncology capabilities” said Peter Casasanto, Chief BioPharma Officer of SOPHiA GENETICS.

“We see AstraZeneca as a visionary partner willing to invest in the next generation of data sciences and technology capabilities at scale to usher in a new area of data-driven medicine. We are incredibly excited to further integrate science and technology in our joint pursuit of transformative impact on patient outcomes” said Dr. Philippe Menu, Chief Medical OfficerSOPHiA GENETICS.

“Multimodality aims to harness the power of advanced AI and machine learning models by integrating multiple data modalities to obtain key insights which inform prognosis and response

to therapy at the individual patient level. This approach is synergistic with AstraZeneca’s focus on developing personalized cancer treatment and has the potential to elevate precision oncology, currently driven by genomic-based biomarkers, into a truly multimodal connected health ecosystem,” said Greg Rossi, Senior Vice President, Oncology Europe & Canada, AstraZeneca.

About SOPHiAGENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn**,**Facebook, and Instagram.Where others see data, we see answers.

SOPHiA GENETICSproducts are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this pressrelease is about products that may or may not be available in different countries and, if applicable, may or may not have received approvalor market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com toobtain the appropriate product information for your country of residence.

SOPHiA GENETICSForward-Looking Statements:

This pressrelease contains statements that constitute forward-looking statements. All statements other than statements of historical facts containedin this press release, including statements regarding our future results of operations and financial position, business strategy, productsand technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-lookingstatements are based on our management’s beliefs and assumptions and on information currently available to our management. Suchstatements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-lookingstatements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurancecan be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only asof the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in thispress release to reflect any change in our expectations

or any changein events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representationsor warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:

Nick Puleo

npuleo@comsint.com

InvestorContact:

Katherine Bailon

IR@sophigenetics.com